Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051406 | 0.98 | DPP3 (0.58) | DPP3BCHECAPN1CTSBCYP2C19 | |
| SCHEMBL29380301 | 0.95 | CAPN1 (0.58) | DPP3BCHECAPN1CTSBNTSR2 | |
| SCHEMBL31127559 | 0.92 | GHSR (0.60) | DPP3BCHEACEGHSRNTSR2 | |
| SCHEMBL30051392 | 0.91 | DPP3 (0.67) | DPP3BCHECAPN1CTSBCYP2C19 | |
| SCHEMBL30051339 | 0.90 | DPP4 (0.58) | DPP3BCHECYP2C19DPP4 | |
| SCHEMBL30311056 | 0.90 | DPP3 (0.52) | DPP3BCHECAPN1CTSBCYP2C19 | |
| SCHEMBL30051552 | 0.90 | DPP3 (0.56) | DPP3BCHECAPN1CTSBDPP4 | |
| SCHEMBL30052939 | 0.89 | DPP3 (0.59) | DPP3BCHECAPN1CTSBCYP2C19 | |
| SCHEMBL30729667 | 0.88 | DPP3 (0.64) | DPP3BCHECAPN1CTSBCYP2C19 | |
| SCHEMBL32681277 | 0.88 | CAPN1 (0.59) | DPP3BCHECAPN1CTSBNTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649267-B2 | Mitrecin A polypeptide with antimicrobial activity | THE MITRE CORPORATION (US) | 2023-05-16 | — | — | US | claimed |
| EP-4602062-A1 | FUSION MOLECULE AND METHOD FOR TREATING IMMUNOLOGICAL DISEASES | Illimis Therapeutics, Inc. (KR) | 2025-08-20 | — | — | EP | disclosed |
| US-12384822-B2 | TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity | ILLIMIS THERAPEUTICS, INC. (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20250154214-A1 | TAM RECEPTOR BINDING FUSION MOLECULE HAVING NON-INFLAMMATORY PHAGOCYTOSIS INDUCING ACTIVITY | ILLIMIS THERAPEUTICS, INC. (KR) | 2025-05-15 | — | — | US | disclosed |
| EP-3094348-B1 | TARGETING IMMUNOLOGICAL FUNCTIONS TO THE SITE OF BACTERIAL INFECTIONS USING CELL WALL TARGETING DOMAINS OF BACTERIOLYSINS | ABVACC INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12116400-B2 | Albumin variants and conjugates | SARTORIUS ALBUMEDIX LIMITED (GB) | 2024-10-15 | — | — | US | disclosed |
| WO-2024205149-A1 | NOVEL GRANZYME FUSION PROTEIN AND USE THEREOF | 카오티에스 주식회사 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024080854-A1 | FUSION MOLECULE AND METHOD FOR TREATING IMMUNOLOGICAL DISEASES | ILLIMIS THERAPEUTICS, INC. (KR) | 2024-04-18 | — | — | WO | disclosed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | disclosed |
| US-11826412-B2 | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids | ABVACC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116848128-A | Fusion molecules with non-inflammatory cell phagocytosis inducing activity | 伊米斯疗法株式会社 | 2023-10-03 | — | — | CN | disclosed |
| US-11649267-B2 | Mitrecin A polypeptide with antimicrobial activity | THE MITRE CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230039076-A1 | ALBUMIN VARIANTS AND CONJUGATES | SARTORIUS ALBUMEDIX LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| US-11555061-B2 | Albumin variants and conjugates | ALBUMEDIX, LTD (GB) | 2023-01-17 | — | — | US | disclosed |
| CN-108137674-B | Albumin variants and conjugates | 阿尔布梅迪克斯医疗有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11421021-B2 | Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides | INTEGRATED BIOTHERAPEUTIC VACCINES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220257744-A1 | IMMUNOGENIC COMPOSITION COMPRISING A FUSION PEPTIDE DERIVED FROM SUPERANTIGEN TOXOIDS | ABVACC, INC. | 2022-08-18 | — | — | US | disclosed |
| WO-2022164288-A1 | FUSION MOLECULE HAVING NON-INFLAMMATORY PHAGOCYTOSIS INDUCING ACTIVITY | 한국과학기술원 | 2022-08-04 | — | — | WO | disclosed |
| US-11260120-B2 | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids | INTEGRATED BIOTHERAPEUTIC VACCINES, INC. (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260120-B2 | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids | GZMB, ST14, SEC11A | DPP3 2039/4885BCHE 1983/4885CAPN1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.